RA Capital Management as of March 31, 2012
Portfolio Holdings for RA Capital Management
RA Capital Management holds 27 positions in its portfolio as reported in the March 2012 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Sequenom | 11.0 | $23M | 5.5M | 4.07 | |
| ArthroCare Corporation | 8.9 | $18M | 683k | 26.85 | |
| Pozen | 8.6 | $18M | 2.9M | 6.00 | |
| XOMA CORP Common equity shares | 7.3 | $15M | 5.4M | 2.77 | |
| BioCryst Pharmaceuticals (BCRX) | 7.2 | $15M | 3.0M | 4.83 | |
| Vanda Pharmaceuticals (VNDA) | 6.0 | $12M | 2.6M | 4.79 | |
| Dyax | 5.9 | $12M | 7.7M | 1.56 | |
| ACADIA Pharmaceuticals (ACAD) | 5.5 | $11M | 5.3M | 2.15 | |
| Derma Sciences | 4.9 | $10M | 1.0M | 9.62 | |
| OncoGenex Pharmaceuticals | 4.8 | $9.9M | 745k | 13.29 | |
| Neurocrine Biosciences (NBIX) | 3.3 | $6.8M | 850k | 7.97 | |
| Vivus | 3.3 | $6.7M | 300k | 22.36 | |
| Verastem | 3.2 | $6.6M | 606k | 10.93 | |
| Synageva Biopharma | 3.2 | $6.5M | 182k | 35.87 | |
| INC Ventrus Biosciences | 2.6 | $5.3M | 535k | 9.97 | |
| Anacor Pharmaceuticals In | 2.3 | $4.7M | 801k | 5.89 | |
| Ym Biosciences | 2.1 | $4.3M | 2.3M | 1.86 | |
| Sangamo Biosciences (SGMO) | 1.7 | $3.5M | 706k | 4.90 | |
| Ardea Biosciences | 1.6 | $3.3M | 150k | 21.76 | |
| Uroplasty | 1.5 | $3.1M | 1.0M | 3.01 | |
| Repros Therapeutics | 1.4 | $2.8M | 667k | 4.23 | |
| Alnylam Pharmaceuticals (ALNY) | 1.4 | $2.8M | 250k | 11.07 | |
| Newlink Genetics Corporation | 1.3 | $2.6M | 289k | 9.15 | |
| Array BioPharma | 0.7 | $1.5M | 440k | 3.40 | |
| Pain Therapeutics | 0.2 | $424k | 117k | 3.62 | |
| Novavax | 0.2 | $378k | 300k | 1.26 | |
| Coronado Biosciences Inc. Common | 0.2 | $353k | 42k | 8.47 |
